inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
Near Add Your Location
Sorting 13 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Not yet accepting
- Show Principal Investigator
- Not yet accepting
- Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Not yet accepting
- Show Principal Investigator
Massachusetts General Hospital
Boston, MA
- Not yet accepting
- Show Principal Investigator
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Not yet accepting
- Show Principal Investigator
Stanford University Cancer Institute (Palo Alto)
Stanford, CA
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Tennessee Oncology - Hayes
Nashville, TN
- Not yet accepting
- Show Principal Investigator
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Not yet accepting
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.